considered to be still out as far as EVAR is concerned in this context.
The authors suggest that the main reason for nonattendance might be because of the deprived nature of the population. However, in Hull and East Yorkshire (which is by any standards an extremely deprived area within the UK) we have a "non-attendance" rate of only 15% with a further 15% cancelling because of personal problems to be later re-booked. This suggests that it is more likely to be the local organisation and structure of the screening program that is critical to maximising attendance.
Perhaps the single most important individual factor is near patient testing. Despite the suggestion of the authors to involve GPs, success has been attained without the involvement of local GPs. After all, these are essentially normal people who do not want to be inconvenienced and they do not need much excuse to justify avoiding attending a clinic. In this regard, the NHS screening program is to be congratulated, as it ensures that everything possible is in place to maximise attendance. 3 The authors are correct to suggest that the use of a prevalence based on the 65e75 year old age group is likely to predict a falsely high number of AAAs. The initial year of the UK national screening program has only looked at 65 year old men. As few men die at 65 from ruptured AAAs, this should not be surprising! However, with the passage of years and long term follow up, the program will almost certainly find AAAs increasing in size until intervention is warranted.
A more worrying issue here is the aorta which measures 2.5e3.0 cm. The UK AAA screening program does not currently mandate these patients to be followed up. Many involved with AAA screening will testify that these patients do in fact show aneurysm tendencies and certainly we have found that at least 50% will have a significant small AAA at 4 years (3.0e4.5) after initial screening which must surely dictate a change of policy in the UK screening program. As the rate of growth is related to AAA size, 4 a follow-up screen at 4 or 5 years must surely be justified. After all, the "patient" will only be 70 years old at that point. Perhaps it is these "missed" subjects, who are indeed at risk of AAA formation, that might partly explain the current relatively low prevalence of AAAs in the UK study?
